US5741908A
(en)
|
1996-06-21 |
1998-04-21 |
Minnesota Mining And Manufacturing Company |
Process for reparing imidazoquinolinamines
|
CA2268957C
(en)
|
1996-10-25 |
2008-04-29 |
Minnesota Mining And Manufacturing Company |
Immune response modifier compounds for treatment of th2 mediated and related diseases
|
UA67760C2
(uk)
|
1997-12-11 |
2004-07-15 |
Міннесота Майнінг Енд Мануфакчурінг Компані |
Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
|
US6110929A
(en)
*
|
1998-07-28 |
2000-08-29 |
3M Innovative Properties Company |
Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
|
US6518280B2
(en)
*
|
1998-12-11 |
2003-02-11 |
3M Innovative Properties Company |
Imidazonaphthyridines
|
US20020058674A1
(en)
|
1999-01-08 |
2002-05-16 |
Hedenstrom John C. |
Systems and methods for treating a mucosal surface
|
US6486168B1
(en)
|
1999-01-08 |
2002-11-26 |
3M Innovative Properties Company |
Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
|
CN1555264A
(zh)
|
1999-01-08 |
2004-12-15 |
3M |
用于治疗粘膜病症的含咪喹莫特或其它免疫应答调节剂的制剂
|
US6558951B1
(en)
*
|
1999-02-11 |
2003-05-06 |
3M Innovative Properties Company |
Maturation of dendritic cells with immune response modifying compounds
|
US6331539B1
(en)
*
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
US6573273B1
(en)
*
|
1999-06-10 |
2003-06-03 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
US6451810B1
(en)
|
1999-06-10 |
2002-09-17 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
US6541485B1
(en)
|
1999-06-10 |
2003-04-01 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
US6756382B2
(en)
|
1999-06-10 |
2004-06-29 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
US6376669B1
(en)
|
1999-11-05 |
2002-04-23 |
3M Innovative Properties Company |
Dye labeled imidazoquinoline compounds
|
US6916925B1
(en)
|
1999-11-05 |
2005-07-12 |
3M Innovative Properties Co. |
Dye labeled imidazoquinoline compounds
|
JP3436512B2
(ja)
*
|
1999-12-28 |
2003-08-11 |
株式会社デンソー |
アクセル装置
|
US6894060B2
(en)
*
|
2000-03-30 |
2005-05-17 |
3M Innovative Properties Company |
Method for the treatment of dermal lesions caused by envenomation
|
US6525064B1
(en)
|
2000-12-08 |
2003-02-25 |
3M Innovative Properties Company |
Sulfonamido substituted imidazopyridines
|
US6660735B2
(en)
*
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Urea substituted imidazoquinoline ethers
|
US6545016B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Amide substituted imidazopyridines
|
US6664265B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
US6545017B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Urea substituted imidazopyridines
|
US6660747B2
(en)
*
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
JP2008531580A
(ja)
*
|
2000-12-08 |
2008-08-14 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答修飾因子の標的化送達のための組成物および方法
|
US6667312B2
(en)
*
|
2000-12-08 |
2003-12-23 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6664260B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Heterocyclic ether substituted imidazoquinolines
|
US6677347B2
(en)
*
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamido ether substituted imidazoquinolines
|
EP1360486A2
(de)
*
|
2000-12-08 |
2003-11-12 |
3M Innovative Properties Company |
Screeningverfahren zur identifizierung von selektiven interferon-alpha-induzierenden verbindungen
|
US6677348B2
(en)
*
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Aryl ether substituted imidazoquinolines
|
UA75622C2
(en)
|
2000-12-08 |
2006-05-15 |
3M Innovative Properties Co |
Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
|
US6664264B2
(en)
*
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US7226928B2
(en)
*
|
2001-06-15 |
2007-06-05 |
3M Innovative Properties Company |
Methods for the treatment of periodontal disease
|
US20030133913A1
(en)
*
|
2001-08-30 |
2003-07-17 |
3M Innovative Properties Company |
Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
|
AU2002360278A1
(en)
*
|
2001-10-12 |
2003-11-11 |
Coley Pharmaceutical Gmbh |
Methods and products for enhancing immune responses using imidazoquinoline compounds
|
DK1719511T3
(da)
*
|
2001-11-16 |
2009-04-14 |
Coley Pharm Group Inc |
N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methansulfonamid, en farmaceutisk sammensætning omfattende samme, og anvendelse deraf
|
ES2312659T3
(es)
*
|
2001-11-29 |
2009-03-01 |
3M Innovative Properties Company |
Formulaciones farmaceuticas que comprenden un modificador de la respuesta inmune.
|
CA2365732A1
(en)
*
|
2001-12-20 |
2003-06-20 |
Ibm Canada Limited-Ibm Canada Limitee |
Testing measurements
|
US6677349B1
(en)
|
2001-12-21 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
JP2005518433A
(ja)
*
|
2002-02-22 |
2005-06-23 |
スリーエム イノベイティブ プロパティズ カンパニー |
Uvb−誘導免疫抑制を軽減し治療する方法
|
DE60325838D1
(de)
*
|
2002-03-19 |
2009-03-05 |
Glaxo Group Ltd |
Imidazoquinolinamine als adjuvantien für hiv dna vakzine
|
AU2003216851B2
(en)
*
|
2002-03-19 |
2008-04-17 |
Powderject Research Limited |
Imidazoquinoline adjuvants for vaccines
|
US8153141B2
(en)
|
2002-04-04 |
2012-04-10 |
Coley Pharmaceutical Gmbh |
Immunostimulatory G, U-containing oligoribonucleotides
|
JP2005538057A
(ja)
|
2002-06-07 |
2005-12-15 |
スリーエム イノベイティブ プロパティズ カンパニー |
エーテル置換イミダゾピリジン
|
AU2003299863B2
(en)
|
2002-08-15 |
2009-09-24 |
3M Innovative Properties Company |
Immunostimulatory compositions and methods of stimulating an immune response
|
AU2003299082A1
(en)
*
|
2002-09-26 |
2004-04-19 |
3M Innovative Properties Company |
1h-imidazo dimers
|
AU2003287324A1
(en)
*
|
2002-12-11 |
2004-06-30 |
3M Innovative Properties Company |
Gene expression systems and recombinant cell lines
|
AU2003287316A1
(en)
*
|
2002-12-11 |
2004-06-30 |
3M Innovative Properties Company |
Assays relating to toll-like receptor activity
|
AU2003301052A1
(en)
|
2002-12-20 |
2004-07-22 |
3M Innovative Properties Company |
Aryl / hetaryl substituted imidazoquinolines
|
US7387271B2
(en)
|
2002-12-30 |
2008-06-17 |
3M Innovative Properties Company |
Immunostimulatory combinations
|
WO2004071459A2
(en)
*
|
2003-02-13 |
2004-08-26 |
3M Innovative Properties Company |
Methods and compositions related to irm compounds and toll-like receptor 8
|
US7485432B2
(en)
*
|
2003-02-27 |
2009-02-03 |
3M Innovative Properties Company |
Selective modulation of TLR-mediated biological activity
|
AU2004218349A1
(en)
|
2003-03-04 |
2004-09-16 |
3M Innovative Properties Company |
Prophylactic treatment of UV-induced epidermal neoplasia
|
CA2517655A1
(en)
*
|
2003-03-07 |
2004-09-23 |
3M Innovative Properties Company |
1-amino 1h-imidazoquinolines
|
US7163947B2
(en)
*
|
2003-03-07 |
2007-01-16 |
3M Innovative Properties Company |
1-Amino 1H-imidazoquinolines
|
CA2518445A1
(en)
|
2003-03-13 |
2004-09-23 |
3M Innovative Properties Company |
Method of tattoo removal
|
WO2004080293A2
(en)
*
|
2003-03-13 |
2004-09-23 |
3M Innovative Properties Company |
Methods for diagnosing skin lesions
|
MXPA05009694A
(es)
*
|
2003-03-13 |
2005-10-20 |
3M Innovative Properties Co |
Metodos para mejorar la calidad de la piel.
|
US20040192585A1
(en)
*
|
2003-03-25 |
2004-09-30 |
3M Innovative Properties Company |
Treatment for basal cell carcinoma
|
ES2423800T3
(es)
|
2003-03-28 |
2013-09-24 |
Novartis Vaccines And Diagnostics, Inc. |
Uso de compuestos orgánicos para la inmunopotenciación
|
AU2004244962A1
(en)
*
|
2003-04-10 |
2004-12-16 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds using metal-containing particulate support materials
|
US20040265351A1
(en)
*
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
EP1617845A4
(de)
*
|
2003-04-28 |
2006-09-20 |
3M Innovative Properties Co |
Zusammensetzungen und verfahren zur induktion von opioid-rezeptoren
|
US7731967B2
(en)
|
2003-04-30 |
2010-06-08 |
Novartis Vaccines And Diagnostics, Inc. |
Compositions for inducing immune responses
|
WO2004110991A2
(en)
*
|
2003-06-06 |
2004-12-23 |
3M Innovative Properties Company |
PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
|
WO2004110992A2
(en)
*
|
2003-06-06 |
2004-12-23 |
3M Innovative Properties Company |
Process for imidazo[4,5-c] pyridin-4-amines
|
RU2006102188A
(ru)
*
|
2003-07-31 |
2006-07-10 |
ЗМ Инновейтив Пропертиз Компани (US) |
Биоактивные композиции, включающие триазины
|
WO2005016273A2
(en)
*
|
2003-08-05 |
2005-02-24 |
3M Innovative Properties Company |
Infection prophylaxis using immune response modifier compounds
|
JP2007502288A
(ja)
*
|
2003-08-12 |
2007-02-08 |
スリーエム イノベイティブ プロパティズ カンパニー |
オキシム置換イミダゾ含有化合物
|
PL1653959T3
(pl)
*
|
2003-08-14 |
2015-10-30 |
3M Innovative Properties Co |
Modyfikatory odpowiedzi immunologicznej modyfikowane lipidami
|
EP1660122A4
(de)
*
|
2003-08-25 |
2007-10-24 |
3M Innovative Properties Co |
Immunstimulatorische kombinationen und behandlungen
|
AU2004268616B2
(en)
*
|
2003-08-25 |
2010-10-07 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds
|
EP1658076B1
(de)
*
|
2003-08-27 |
2013-03-06 |
3M Innovative Properties Company |
Aryloxy- und arylalkylenoxy-substituierte imidazochinoline
|
JP2007504172A
(ja)
*
|
2003-09-02 |
2007-03-01 |
スリーエム イノベイティブ プロパティズ カンパニー |
粘膜に関連した症状の処置に関する方法
|
AU2004270201A1
(en)
*
|
2003-09-05 |
2005-03-17 |
3M Innovative Properties Company |
Treatment for CD5+ B cell lymphoma
|
EP1664342A4
(de)
*
|
2003-09-17 |
2007-12-26 |
3M Innovative Properties Co |
Selektive modulation der expression des tlr-gens
|
AU2004315876B2
(en)
|
2003-10-03 |
2011-05-26 |
3M Innovative Properties Company |
Pyrazolopyridines and analogs thereof
|
US7544697B2
(en)
*
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
BRPI0414856A
(pt)
|
2003-10-03 |
2006-11-21 |
3M Innovative Properties Co |
imidazoquinolinas alcóxi-substituìdas
|
US20090075980A1
(en)
*
|
2003-10-03 |
2009-03-19 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and Analogs Thereof
|
WO2005041891A2
(en)
*
|
2003-10-31 |
2005-05-12 |
3M Innovative Properties Company |
Neutrophil activation by immune response modifier compounds
|
CA2545774A1
(en)
*
|
2003-11-14 |
2005-06-02 |
3M Innovative Properties Company |
Oxime substituted imidazo ring compounds
|
WO2005048945A2
(en)
|
2003-11-14 |
2005-06-02 |
3M Innovative Properties Company |
Hydroxylamine substituted imidazo ring compounds
|
US8778963B2
(en)
*
|
2003-11-25 |
2014-07-15 |
3M Innovative Properties Company |
Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
US8691837B2
(en)
|
2003-11-25 |
2014-04-08 |
3M Innovative Properties Company |
Substituted imidazo ring systems and methods
|
US8940755B2
(en)
*
|
2003-12-02 |
2015-01-27 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
US20050226878A1
(en)
*
|
2003-12-02 |
2005-10-13 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
AU2004315771A1
(en)
*
|
2003-12-04 |
2005-08-25 |
3M Innovative Properties Company |
Sulfone substituted imidazo ring ethers
|
WO2005066170A1
(en)
*
|
2003-12-29 |
2005-07-21 |
3M Innovative Properties Company |
Arylalkenyl and arylalkynyl substituted imidazoquinolines
|
WO2005066172A1
(en)
*
|
2003-12-29 |
2005-07-21 |
3M Innovative Properties Company |
Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
|
EP1699398A4
(de)
*
|
2003-12-30 |
2007-10-17 |
3M Innovative Properties Co |
Verbesserung der immunantworten
|
US8735421B2
(en)
*
|
2003-12-30 |
2014-05-27 |
3M Innovative Properties Company |
Imidazoquinolinyl sulfonamides
|
CA2559607C
(en)
*
|
2004-03-15 |
2013-02-19 |
3M Innovative Properties Company |
Immune response modifier formulations and methods
|
WO2005094531A2
(en)
*
|
2004-03-24 |
2005-10-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
AU2005244260B2
(en)
*
|
2004-04-09 |
2010-08-05 |
3M Innovative Properties Company |
Methods, compositions, and preparations for delivery of immune response modifiers
|
JP2008505857A
(ja)
*
|
2004-04-28 |
2008-02-28 |
スリーエム イノベイティブ プロパティズ カンパニー |
粘膜ワクチン接種のための組成物および方法
|
US20090104226A1
(en)
|
2004-05-21 |
2009-04-23 |
Novartis Vaccines And Diagnostics Inc. |
Alphavirus Vectors for Respiratory Pathogen Vaccines
|
US20050267145A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
US20080015184A1
(en)
*
|
2004-06-14 |
2008-01-17 |
3M Innovative Properties Company |
Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
|
WO2005123080A2
(en)
*
|
2004-06-15 |
2005-12-29 |
3M Innovative Properties Company |
Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
WO2006038923A2
(en)
*
|
2004-06-18 |
2006-04-13 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
US8541438B2
(en)
|
2004-06-18 |
2013-09-24 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
WO2006009826A1
(en)
*
|
2004-06-18 |
2006-01-26 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
EP1765348B1
(de)
*
|
2004-06-18 |
2016-08-03 |
3M Innovative Properties Company |
Substituierte imidazochinoline, imidazopyridine sowie imidazonaphthyridine
|
WO2006065280A2
(en)
*
|
2004-06-18 |
2006-06-22 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
|
CA2571710A1
(en)
|
2004-06-24 |
2006-11-02 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
EP1765313A2
(de)
|
2004-06-24 |
2007-03-28 |
Novartis Vaccines and Diagnostics, Inc. |
Verbindungen als immunstimulatoren
|
EP1786450A4
(de)
*
|
2004-08-27 |
2009-11-11 |
3M Innovative Properties Co |
Hiv-immunstimulatorische zusammensetzungen
|
US20090270443A1
(en)
*
|
2004-09-02 |
2009-10-29 |
Doris Stoermer |
1-amino imidazo-containing compounds and methods
|
CA2578741C
(en)
*
|
2004-09-02 |
2014-01-14 |
3M Innovative Properties Company |
1-alkoxy 1h-imidazo ring systems and methods
|
CA2578975A1
(en)
|
2004-09-02 |
2006-03-16 |
3M Innovative Properties Company |
2-amino 1h imidazo ring systems and methods
|
WO2006029223A2
(en)
*
|
2004-09-08 |
2006-03-16 |
Children's Medical Center Corporation |
Method for stimulating the immune response of newborns
|
RU2415857C2
(ru)
*
|
2004-09-14 |
2011-04-10 |
Новартис Вэксинс Энд Диагностикс Инк. |
Имидазохинолиновые соединения
|
WO2006042254A2
(en)
*
|
2004-10-08 |
2006-04-20 |
3M Innovative Properties Company |
Adjuvant for dna vaccines
|
WO2006063072A2
(en)
*
|
2004-12-08 |
2006-06-15 |
3M Innovative Properties Company |
Immunomodulatory compositions, combinations and methods
|
US8080560B2
(en)
|
2004-12-17 |
2011-12-20 |
3M Innovative Properties Company |
Immune response modifier formulations containing oleic acid and methods
|
CA2594674C
(en)
*
|
2004-12-30 |
2016-05-17 |
3M Innovative Properties Company |
Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
|
CA2592897A1
(en)
*
|
2004-12-30 |
2006-07-13 |
Takeda Pharmaceutical Company Limited |
1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate
|
US8436176B2
(en)
*
|
2004-12-30 |
2013-05-07 |
Medicis Pharmaceutical Corporation |
Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
|
ES2538498T3
(es)
|
2004-12-30 |
2015-06-22 |
Meda Ab |
Utilización de Imiquimod para el tratamiento de metástasis cutáneas provenientes de un tumor de cáncer de mama
|
WO2006074003A2
(en)
*
|
2004-12-30 |
2006-07-13 |
3M Innovative Properties Company |
CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS
|
US9248127B2
(en)
*
|
2005-02-04 |
2016-02-02 |
3M Innovative Properties Company |
Aqueous gel formulations containing immune response modifiers
|
AU2006212765B2
(en)
|
2005-02-09 |
2012-02-02 |
3M Innovative Properties Company |
Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
|
CA2602083A1
(en)
|
2005-02-09 |
2006-08-09 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
|
US7968563B2
(en)
|
2005-02-11 |
2011-06-28 |
3M Innovative Properties Company |
Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
|
JP2008530112A
(ja)
*
|
2005-02-11 |
2008-08-07 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
置換縮合[1,2]イミダゾ「4,5−c]環化合物および方法
|
US8658666B2
(en)
*
|
2005-02-11 |
2014-02-25 |
3M Innovative Properties Company |
Substituted imidazoquinolines and imidazonaphthyridines
|
JP2008530245A
(ja)
|
2005-02-18 |
2008-08-07 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
尿路病原性菌株由来の抗原
|
WO2006089264A2
(en)
|
2005-02-18 |
2006-08-24 |
Novartis Vaccines And Diagnostics Inc. |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
EP1850849A2
(de)
*
|
2005-02-23 |
2007-11-07 |
Coley Pharmaceutical Group, Inc. |
Verfahren zur vorzugsweisen herbeiführung der biosynthese von interferon
|
CA2598639A1
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Hydroxyalkyl substituted imidazonaphthyridines
|
US8158794B2
(en)
*
|
2005-02-23 |
2012-04-17 |
3M Innovative Properties Company |
Hydroxyalkyl substituted imidazoquinoline compounds and methods
|
CA2598695A1
(en)
*
|
2005-02-23 |
2006-09-21 |
Coley Pharmaceutical Group, Inc. |
Hydroxyalkyl substituted imidazoquinolines
|
AU2006223148A1
(en)
|
2005-03-14 |
2006-09-21 |
3M Innovative Properties Company |
Method of treating actinic keratosis
|
AU2006232375A1
(en)
|
2005-04-01 |
2006-10-12 |
Coley Pharmaceutical Group, Inc. |
1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
|
EP1869043A2
(de)
|
2005-04-01 |
2007-12-26 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridin-1,4-diamine und analoge davon
|
JP2008539252A
(ja)
*
|
2005-04-25 |
2008-11-13 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫活性化組成物
|
CA2615626A1
(en)
|
2005-07-18 |
2007-01-25 |
Novartis Ag |
Small animal model for hcv replication
|
ZA200803029B
(en)
*
|
2005-09-09 |
2009-02-25 |
Coley Pharm Group Inc |
Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
|
US8476292B2
(en)
*
|
2005-09-09 |
2013-07-02 |
3M Innovative Properties Company |
Amide and carbamate derivatives of N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1-dimethylethyl}methanesulfonamide and methods
|
US8889154B2
(en)
|
2005-09-15 |
2014-11-18 |
Medicis Pharmaceutical Corporation |
Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
|
EP1945247A1
(de)
|
2005-10-18 |
2008-07-23 |
Novartis Vaccines and Diagnostics, Inc. |
Mukosale und systemische immunisierungen mit alphavirus-replicon-teilchen
|
CA2628328A1
(en)
|
2005-11-04 |
2007-05-10 |
Novartis Vaccines And Diagnostics S.R.L. |
Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
|
US20090304742A1
(en)
|
2005-11-04 |
2009-12-10 |
Novartis Vaccines And Diagnostics Srl |
Influenza vaccines with reduced amount of emulsion adjuvant
|
CA2628424A1
(en)
|
2005-11-04 |
2007-05-10 |
Novartis Vaccines And Diagnostics S.R.L. |
Adjuvanted influenza vaccines including cytokine-inducing agents
|
EP1948173B1
(de)
|
2005-11-04 |
2013-07-17 |
3M Innovative Properties Company |
Hydroxy- und alkoxy-substituierte 1h-imidazochinoline und verfahren
|
HUE051122T2
(hu)
|
2005-11-04 |
2021-03-01 |
Seqirus Uk Ltd |
Sejttenyészetben növesztett influenzavírusból elõállított nemvirion anti-géneket tartalmazó adjuvált vakcinák
|
ES2514316T3
(es)
|
2005-11-22 |
2014-10-28 |
Novartis Vaccines And Diagnostics, Inc. |
Partículas similares a virus (VLPs) de Norovirus y Sapovirus
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
PT2478916T
(pt)
|
2006-01-27 |
2020-07-03 |
Seqirus Uk Ltd |
Vacinas de influenza que contêm hemaglutinina e proteínas da matriz
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
EP3085373A1
(de)
|
2006-02-22 |
2016-10-26 |
3M Innovative Properties Company |
Konjugate zur modifizierung von immunreaktionen
|
WO2007106852A2
(en)
*
|
2006-03-15 |
2007-09-20 |
Coley Pharmaceutical Group, Inc. |
Substituted fused[1,2]imidazo[4,5-c] ring compounds and methods
|
WO2007106854A2
(en)
*
|
2006-03-15 |
2007-09-20 |
Coley Pharmaceutical Group, Inc. |
Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
|
CA2646891A1
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Immunopotentiating compounds
|
EP2010530A2
(de)
*
|
2006-03-23 |
2009-01-07 |
Novartis AG |
Herstellungsverfahren für imidazolhaltige verbindungen
|
WO2007109813A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
EP2382987A1
(de)
|
2006-03-24 |
2011-11-02 |
Novartis Vaccines and Diagnostics GmbH |
Lagerung von Influenza-Impfstoffen ohne Kühlung
|
CA2647942A1
(en)
|
2006-03-31 |
2007-11-08 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
TW200808739A
(en)
*
|
2006-04-06 |
2008-02-16 |
Novartis Vaccines & Diagnostic |
Quinazolines for PDK1 inhibition
|
US20100015168A1
(en)
|
2006-06-09 |
2010-01-21 |
Novartis Ag |
Immunogenic compositions for streptococcus agalactiae
|
US7906506B2
(en)
*
|
2006-07-12 |
2011-03-15 |
3M Innovative Properties Company |
Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
US20100166788A1
(en)
|
2006-08-16 |
2010-07-01 |
Novartis Vaccines And Diagnostics |
Immunogens from uropathogenic escherichia coli
|
US8178539B2
(en)
*
|
2006-09-06 |
2012-05-15 |
3M Innovative Properties Company |
Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
|
ES2536401T3
(es)
|
2006-09-11 |
2015-05-25 |
Novartis Ag |
Fabricación de vacunas contra virus de la gripe sin usar huevos
|
US20110045022A1
(en)
|
2006-12-06 |
2011-02-24 |
Theodore Tsai |
Vaccines including antigen from four strains of influenza virus
|
US20080149123A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
PT2185191E
(pt)
|
2007-06-27 |
2012-11-27 |
Novartis Ag |
Vacinas contra a gripe com baixo teor de aditivos
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
US8287885B2
(en)
|
2007-09-12 |
2012-10-16 |
Novartis Ag |
GAS57 mutant antigens and GAS57 antibodies
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
UY31545A1
(es)
|
2007-12-20 |
2009-08-03 |
|
Nuevos derivados de 2-carboxamida cianoaminourea, sus sales y profarmacos farmacéuticamente aceptables, procesos de preparacion y aplicaciones
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
NZ586430A
(en)
|
2007-12-21 |
2012-09-28 |
Novartis Ag |
Mutant forms of streptolysin o (slo)
|
EP2268309B1
(de)
|
2008-03-18 |
2015-01-21 |
Novartis AG |
Verbesserungen der herstellung von grippevirus-impstoff-antigenen
|
CN101717397B
(zh)
*
|
2008-10-09 |
2012-11-28 |
中国科学院上海药物研究所 |
一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物
|
US8585505B2
(en)
|
2008-12-15 |
2013-11-19 |
Tetris Online, Inc. |
Inter-game interactive hybrid asynchronous computer game infrastructure
|
MX2011007456A
(es)
|
2009-01-12 |
2011-08-03 |
Novartis Ag |
Antigenos del dominio de proteina de superficie de union a colageno tipo b (can_b) en vacunas contra bacteria gram positiva.
|
AU2010220103A1
(en)
|
2009-03-06 |
2011-09-22 |
Novartis Ag |
Chlamydia antigens
|
AU2010229835B2
(en)
|
2009-03-25 |
2015-01-15 |
The Board Of Regents Of The University Of Texas System |
Compositions for stimulation of mammalian innate immune resistance to pathogens
|
SG175092A1
(en)
|
2009-04-14 |
2011-11-28 |
Novartis Ag |
Compositions for immunising against staphylococcus aerus
|
USH2283H1
(en)
|
2009-04-27 |
2013-09-03 |
Novartis Ag |
Vaccines for protecting against influenza
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
SG178026A1
(en)
|
2009-07-15 |
2012-03-29 |
Novartis Ag |
Rsv f protein compositions and methods for making same
|
ES2526996T3
(es)
|
2009-07-16 |
2015-01-19 |
Novartis Ag |
Inmunógenos desintoxicados de Escherichia coli
|
US20110033515A1
(en)
*
|
2009-08-04 |
2011-02-10 |
Rst Implanted Cell Technology |
Tissue contacting material
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
WO2011130379A1
(en)
|
2010-04-13 |
2011-10-20 |
Novartis Ag |
Benzonapthyridine compositions and uses thereof
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
HUE033901T2
(en)
|
2010-08-17 |
2018-01-29 |
3M Innovative Properties Co |
Formulations and formulations for lipidized immune response modifying compounds and related processes
|
AU2012211278B2
(en)
|
2011-01-26 |
2016-11-10 |
Glaxosmithkline Biologicals Sa |
RSV immunization regimen
|
PT2670753T
(pt)
|
2011-01-31 |
2017-01-10 |
Novartis Ag |
Novos derivados heterocíclicos
|
LT2707385T
(lt)
|
2011-05-13 |
2017-12-11 |
Glaxosmithkline Biologicals Sa |
Iš anksto sulieti rsv f antigenai
|
JP6460789B2
(ja)
|
2011-06-03 |
2019-01-30 |
スリーエム イノベイティブ プロパティズ カンパニー |
ポリエチレングリコールセグメントを有するヘテロ2官能性リンカー及び該リンカーから調製された免疫反応調節複合体
|
CA2838023C
(en)
|
2011-06-03 |
2019-08-13 |
3M Innovative Properties Company |
Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
|
EP3332802A1
(de)
|
2011-07-06 |
2018-06-13 |
GlaxoSmithKline Biologicals SA |
Immunogene kombinationszusammensetzungen und ihre verwendung
|
EP3508219A1
(de)
|
2011-07-06 |
2019-07-10 |
GlaxoSmithKline Biologicals S.A. |
Selbst-replizierende rna-prime - protein boost impfstoffe
|
US20130023736A1
(en)
|
2011-07-21 |
2013-01-24 |
Stanley Dale Harpstead |
Systems for drug delivery and monitoring
|
EP2771342B1
(de)
|
2011-10-28 |
2016-05-18 |
Novartis AG |
Purinderivate und ihre verwendung bei der behandlung von krankheiten
|
US9493517B2
(en)
|
2011-11-07 |
2016-11-15 |
Glaxosmithkline Biologicals Sa |
Conjugates comprising an antigen and a carrier molecule
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
PE20142406A1
(es)
|
2012-05-04 |
2015-01-23 |
Pfizer |
Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
|
WO2013173283A1
(en)
|
2012-05-16 |
2013-11-21 |
Novartis Ag |
Dosage regimen for a pi-3 kinase inhibitor
|
CN104853770A
(zh)
|
2012-07-06 |
2015-08-19 |
诺华股份有限公司 |
免疫原性组合物及其应用
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
EP2941233B1
(de)
|
2013-01-07 |
2020-10-07 |
The Trustees of the University of Pennsylvania |
Zusammensetzungen und verfahren zur behandlung von t-zelllymphom
|
CN105142611B
(zh)
|
2013-03-10 |
2019-06-04 |
佩丽泰克医药有限公司 |
外用组合物及治疗局部病症的方法
|
EP3632458A1
(de)
|
2013-07-26 |
2020-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verbindungen und pharmazeutische zusammensetzungen zur behandlung von bakterieninfektionen
|
AU2014347059B2
(en)
|
2013-11-05 |
2017-09-07 |
Solventum Intellectual Properties Company |
Sesame oil based injection formulations
|
EP2870974A1
(de)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella-Konjugatimpfstoffe
|
PT3076969T
(pt)
|
2013-12-06 |
2021-11-23 |
Novartis Ag |
Regime de dosagem de um inibidor de fosfatidilinositol 3- quinase seletivo para a isoforma alfa
|
WO2015103989A1
(en)
|
2014-01-10 |
2015-07-16 |
Shanghai Birdie Biotech, Inc. |
Compounds and compositions for immunotherapy
|
EP3094342A4
(de)
|
2014-01-15 |
2017-12-27 |
Nikolai Khodarev |
Antitumortherapie
|
KR102297357B1
(ko)
|
2014-03-26 |
2021-09-02 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
돌연변이 스태필로코쿠스 항원
|
CN112546231A
(zh)
|
2014-07-09 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
DK3166976T3
(da)
|
2014-07-09 |
2022-04-11 |
Birdie Biopharmaceuticals Inc |
Anti-pd-l1-kombinationer til behandling af tumorer
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
US10526309B2
(en)
|
2015-10-02 |
2020-01-07 |
The University Of North Carolina At Chapel Hill |
Pan-TAM inhibitors and Mer/Axl dual inhibitors
|
MX2018005298A
(es)
|
2015-11-02 |
2018-06-22 |
Novartis Ag |
Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
|
CN106943596A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技(北京)有限公司 |
用于治疗肿瘤的抗-cd20组合
|
CN115252792A
(zh)
|
2016-01-07 |
2022-11-01 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-egfr组合
|
CN115350279A
(zh)
|
2016-01-07 |
2022-11-18 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-her2组合
|
WO2018038877A1
(en)
*
|
2016-08-26 |
2018-03-01 |
3M Innovative Properties Company |
FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS SUBSTITUTED WITH GUANIDINO GROUPS
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
AU2017356673B2
(en)
|
2016-11-09 |
2023-11-09 |
Pulmotect, Inc. |
Methods and compositions for adaptive immune modulation
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
CA3067268A1
(en)
|
2017-06-23 |
2018-12-27 |
Birdie Biopharmaceuticals, Inc. |
Crystalline resiquimod monosulfate anhydrate and its preparation and uses
|
US11306083B2
(en)
|
2017-12-20 |
2022-04-19 |
3M Innovative Properties Company |
Amide substituted imidazo[4,5-C]quinoline compounds with a branched chain linking group for use as an immune response modifier
|
KR20200128116A
(ko)
|
2018-02-28 |
2020-11-11 |
화이자 인코포레이티드 |
Il-15 변이체 및 이의 용도
|
EP3797121A1
(de)
|
2018-05-23 |
2021-03-31 |
Pfizer Inc |
Cd3-spezifische antikörper und verwendungen davon
|
CA3100829A1
(en)
|
2018-05-23 |
2019-11-28 |
Pfizer Inc. |
Antibodies specific for gucy2c and uses thereof
|
US20220370606A1
(en)
|
2018-12-21 |
2022-11-24 |
Pfizer Inc. |
Combination Treatments Of Cancer Comprising A TLR Agonist
|
WO2021116420A1
(en)
|
2019-12-13 |
2021-06-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis
|
MX2022006578A
(es)
|
2019-12-17 |
2022-07-04 |
Pfizer |
Anticuerpos especificos para cd47, pd-l1 y sus usos.
|
JP2023533793A
(ja)
|
2020-07-17 |
2023-08-04 |
ファイザー・インク |
治療用抗体およびそれらの使用
|